Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of ($0.04) for the quarter, down from their prior forecast of $0.03. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' FY2025 earnings at $0.07 EPS, Q2 2026 earnings at $0.06 EPS and FY2027 earnings at ($0.01) EPS.
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $41.14 million for the quarter, compared to the consensus estimate of $67.02 million.
A number of other equities research analysts also recently weighed in on the stock. Jefferies Financial Group reaffirmed a "hold" rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Wells Fargo & Company restated an "equal weight" rating and issued a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Leerink Partners decreased their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research report on Monday, April 14th. Finally, Craig Hallum cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $4.78.
Read Our Latest Stock Report on IRWD
Ironwood Pharmaceuticals Price Performance
Shares of NASDAQ:IRWD traded up $0.02 during trading on Monday, reaching $0.62. 2,139,575 shares of the company's stock traded hands, compared to its average volume of 2,586,514. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $7.11. The company has a 50 day moving average of $0.89 and a 200-day moving average of $2.26. The stock has a market capitalization of $100.33 million, a P/E ratio of -20.67 and a beta of 0.37.
Institutional Trading of Ironwood Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Ironwood Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after acquiring an additional 3,209 shares during the period. Swiss National Bank lifted its stake in shares of Ironwood Pharmaceuticals by 2.2% in the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock worth $1,252,000 after acquiring an additional 6,000 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Ironwood Pharmaceuticals by 19.6% in the 4th quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 7,020 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, MetLife Investment Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 10.6% in the 4th quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company's stock worth $395,000 after acquiring an additional 8,559 shares during the period.
About Ironwood Pharmaceuticals
(
Get Free Report)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
Featured Stories
Before you consider Ironwood Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.
While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
